Table 2. Global drug adaptations during COVID-19 pandemic.

Treatment	Drugs	Recommendations
Supportive care measures	G-CSF	Intermediate and high risk of neutropenia
	Erythropoietin	In metastatic disease Hemoglobin <10 g/dl
	Corticosteroids	Reduce using in pre-medication
	Intravenous bisphosphonate injections	Switch to 3 monthly schedule
Chemotherapy	Weekly protocol	Switch to 3 weekly protocol
	Cisplatin	Replace by Carboplatin or oxaliplatin, except malignant germ cell tumors
	5-Fluorouracil	Replace by capecitabine
	Vinorelbine	Use oral presentation
	Metastatic disease	Switch to oral chemotherapy if possible (e.g., breast cancer)
Endocrine therapy	All	No change
Target therapy	All	No change
Immunotherapy	Pembrolizumab	400 mg every 6 weeks
	Atezolizumab	1680 mg every 4 weeks